Chargement en cours...
Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity
T cell-invigorating cancer immunotherapies have near-curative potential. However, their clinical benefit is currently limited, as only a fraction of patients respond, suggesting that these regimens may benefit from combination with tumor-targeting treatments. As oncogenic progression is accompanied...
Enregistré dans:
| Publié dans: | Proc Natl Acad Sci U S A |
|---|---|
| Auteurs principaux: | , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
National Academy of Sciences
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6511047/ https://ncbi.nlm.nih.gov/pubmed/31019077 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1814932116 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|